article

European Pharmaceutical Review Issue 3 2019

In this issue we explore reasons behind critical key drug shortages in the EU, whether viability methods effectively detect all viable organisms and how companies can future-proof their digital technologies ahead of Brexit. Also included are articles on higher order protein structure, FMD compliance and Raman spectroscopy.

Included in this issue:

  • REGULATORY INSIGHT
    Tadalafil UKSC decision: evolution of the multi-factorial approach
    Dr Matthew Royle and Taylor Wessing
  • BREXIT
    Brexit-tech: overcoming post-brexit challenges by driving operational and cost efficiencies 
    Neal Singh, Icertis
  • BIOPROCESSING & BIOPRODUCTION
    Analytical methods used in obtaining higher order structure information from protein therapeutics
    Ioannis A. Papayannopoulos and Shannon Renn-Bingham, Celldex Therapeutics, Inc.
  • FORMULATION, DEVELOPMENT & DELIVERY
    Capsosomes: the revolutionary enzyme carriers
    Marc Baiget Francesch
  • QA/QC AND ANALTICAL TECHNIQUES
    Do viability methods detect all viable organisms?
    Jeanne Moldenhauer, Excellent Pharma Consulting, Inc
  • MANUFACTURING, PACKAGING & LOGISTICS
    Manufacturing medical devices to ISO 13485:2016
    Jessica Clifton

The rest of this content is restricted - login or subscribe free to access

Issue 1 Front coverThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • bi-monthly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here

 

Send this to a friend